FDA approves mitomycin intravesical solution for recurrent low-grade
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade
Related Articles
Vita-Warehouse Corp. Issues Allergy Alert on Undeclared Peanut Allergen in ALDI Welby®, Berkley Jensen®, and VitaGlobe™ Vitamin B12 Gummy Products
June 12, 2025, Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely…
AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research
This award recognizes an individual in any sector who has significantly contributed to any aspect of pediatric cancer research.
Sensorized Guidewire Issue from Centerline Biomedical
Sensorized Guidewire Issue from Centerline Biomedical
Pembrolizumab’s Perioperative Power in Head and Neck Cancer
Adding pembrolizumab before and after surgery to standard of care improved outcomes in previously untreated head and neck cancer patients.
FDA approves neoadjuvant and adjuvant pembrolizumab for resectable loc
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
Program: Thursday, September 18
thursday, September 18 Conference Registration 1:30-7:00 p.m. Welcome and Opening Session 4-6 p.m. | CME-eligible Minorities in Cancer Research (MICR) Meet and Greet 6-7 p.m.…
AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research – Emerging Science Driving Transformative Solutions
Meeting overview details for AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research – Emerging Science Driving Transformative Solutions
FDA approves neoadjuvant and adjuvant pembrolizumab for resectable loc
On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with resectable locally advanced head and neck squamous c
Nipro Liquid Bicarbonate Dialysate Concentrate Contamination Recall
Nipro recalls bicarbonate dialysate concentrate due to contamination. Learn about potential serious injuries, fatality risks and essential steps for healthcare providers and patients for this…
Share Your Story
As a patient, survivor, or caregiver, your story can provide hope and inspiration to someone who’s been diagnosed with cancer or is undergoing therapy.